Oxford BioTherapeutics uses Amgen’s Xenomouse antibodies for breast cancer

UK biotech company Oxford BioTherapeutics has obtained the exclusive global rights to USA-based Amgen’s (Nasdaq: AMGN) Xenomouse antibodies to ImmunoGen’s (Nasdaq: IMGN) maytansinoid ADC technology for an undisclosed target.

The rights were granted under the existing strategic collaboration between Oxford BioTherapeutics and Amgen. Oxford BioTherapeutics intends to use the antibodies and ADC technology to develop a novel ADC targeting a protein in HER2-negative breast cancer, initially focusing on triple negative breast cancer, and other cancers, where the target is expressed. The target was identified using the company’s OGAP discovery technology.

Oxford chief executive Christian Rohlff said: “Obtaining these global rights represents a further strategic milestone for Oxford BioTherapeutics, as we complete our transition into a fully-fledged antibody-based cancer therapy business. By combining these antibodies and antibody ‘arming’ technology with our unique cancer target, we have the opportunity to develop an important new treatment for women with triple negative breast cancer who currently have limited therapeutic options.”